Margot Robbie “defines any attempts at lazy categorisation”, says Roisin Kelly in The Times. “Blonde Aussie bombshell and global pin-up? Yes, of course. But she has also become a mogul”: a producer, investor and, as of last month, “now a liquor baron too” – she has started her own gin brand, Papa Salt.
Robbie, 34, is perhaps best known for her starring role in the hit film Barbie, which brought in $1.4 billion, and was produced by a company she founded, LuckyChap, which has racked up 25 Academy Award nominations, 18 Bafta nominations and raked in billions in box-office takings worldwide. Robbie first won fame playing Jordan Belfort’s wife in The Wolf of Wall Street and for her Academy Award-winning role as figure skater Tonya Harding in I, Tonya. Forbes puts her estimated net worth at £46 million.
She has come a long way from humble beginnings, says Julianna Cabili for Tatler Asia. Before making her way to the US, Robbie made a name for herself as a recurring actress in the long-running Australian soap opera Neighbours. She left the series in 2011 to pursue a career in Hollywood. Making it there was more challenging than launching a gin brand, says Robbie. There, you’re basically selling an unproven idea. Gin is at least a tangible product.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Robbie is, of course, “far from the first A-lister to stick her name on a booze brand”, says Kelly. Everyone from Brad Pitt to Ozzy Osbourne has “waded into” the gin industry, a global market worth £12.7 billion. Gary Barlow and Snoop Dogg are making wine, Kendall Jenner has backed a tequila and Cate Blanchett is the creative director of a saké brand. But Robbie and her husband and business partner have no further plans for conquering this world. “Our passions are movies and drinks,” says Robbie. “And now we’ve ticked them both.”
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Review: The Grill at the DorchesterThe Grill at the Dorchester has a new, easy-going atmosphere, but the food is serious: from punchy beef wellington to grown-up tarte tatin, says Dan McEvoy
-
Review: The Hut, Colwell Bay – a seafood lunch with a holiday feelTravel Getting to The Hut in Colwell Bay on the Isle of Wight is almost as rewarding as actually eating there
-
Pierre-Édouard Stérin wants to make France great againConservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging marketsOpinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growthPinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summerThe US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with folliesThe best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuationAEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefullyShares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
